Psycho Analyst
Contributor since: 2013
Latest Articles
Did Screening 340 Mid-Cap Value Stocks With F.A.S.T. Graphs Pay Off?
Industry Leaders: Relaxing FDA Standards Will Kill The Pharma Golden Goose
Screening For Profitable, Robustly Growing Companies Suitable For Long Term Buy And Hold
I Screened These 340 Mid-Cap Stocks So You Don't Have To
Amazon: The Gray Swan About To Destroy The Value Of Your Consumer Staples And Retailer Dividend Stocks
Did Your 2015 Stock Picks Do Better Than These Hedge Fund Chosen 'Winners'
Can Today's Cash Flow Per Share Or Market Capitalization Help Us Find The Dividend Aristocrats Of The Future?
Did P/E Ratio Or PEG Ratio Predict Total Dividends Paid Or Total Return For These Top 13 Dividend Aristocrats?
How The Survival Bias 13 Did Between 2008 And Now And 2011 And Now: Total Returns Vs. Dividends Part 2
This Total Return Vs. Dividends Smack Down Between 13 Top Dividend Aristocrat Survivors Will Wake You Up
The Fate Of These 49 'Dividend Aristocrats' Of The Early 1990s May Give You Nightmares
These 26 Dividend Aristocrats Won't Let You Sleep Well At Night
Analysts Do A Great Job Predicting The Past. The Future? Not So Much.
Yes, You Can Find 'Alpha' In Fixed Income - In Safe, 100% Insured CDs
Retirees: Are You Seeing The Face Of Jesus In A Piece Of Toast?
Why Confirmation Bias Is A Portfolio Killer
The Well-Valued Growth Portfolio Proves Its Worth During The Correction
Lessons Learned: Time To Simplify The Well-Valued Growth Portfolio
The Biggest Threat To Your Retirement Portfolio: Mild Dementia
Time To Take Profits In The Rebounding Well-Valued Growth Portfolio
The Well-Valued Growth Portfolio Has A Rocky Month As More Holdings Go Out Of Value
LGI Homes A Contrarian Pick With An Exceptional Upside
The Well-Valued Growth Portfolio Continues To Outperform The S&P And Nasdaq Indexes
A Case Study: Growth Investing Using F.A.S.T. Graphs Software To Analyze Fundamentals
New Buy Ins And Profit Taking: The Well-Valued Growth Portfolio This Month
More Insight Into MannKind's Near-Term Profitability
No MannKind Buyout Until Afrezza Is Profitable
MannKind Investors: Don't Screw Up The Afrezza Launch
What MannKind Investors Can Learn From The Sanofi Conference Call
My Well-Valued Growth Portfolio Beats The S&P 500 For January
MannKind: Great Afrezza Word Of Mouth, But Prescriptions Won't Soar Right Away
A New Price Estimate Now That Afrezza Is Launching